There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Avenue Therapeutics (ATXI – Research Report), Eli Lilly & Co (LLY – Research Report) and Cytokinetics (CYTK – Research Report) with bullish sentiments.
Avenue Therapeutics (ATXI)
In a report issued on October 7, Jason Kolbert from Dawson James maintained a Buy rating on Avenue Therapeutics, with a price target of $24.00. The company’s shares closed last Monday at $2.58, close to its 52-week low of $2.29.
According to TipRanks.com, Kolbert has 0 stars on 0-5 stars ranking scale with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Avenue Therapeutics with a $24.00 average price target.
See Insiders’ Hot Stocks on TipRanks >>
Eli Lilly & Co (LLY)
BMO Capital analyst Evan Seigerman maintained a Buy rating on Eli Lilly & Co on October 7 and set a price target of $396.00. The company’s shares closed last Monday at $323.89, close to its 52-week high of $341.70.
According to TipRanks.com, Seigerman is a 4-star analyst with an average return of
Eli Lilly & Co has an analyst consensus of Strong Buy, with a price target consensus of $373.63, which is a 14.5% upside from current levels. In a report issued on September 22, UBS also upgraded the stock to Buy with a $363.00 price target.
Cytokinetics (CYTK)
Mizuho Securities analyst Salim Syed assigned a Buy rating to Cytokinetics yesterday and set a price target of $80.00. The company’s shares closed last Monday at $47.23.
According to TipRanks.com, Syed is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Cytokinetics has an analyst consensus of Strong Buy, with a price target consensus of $68.11, which is a 42.6% upside from current levels. In a report issued on October 3, JMP Securities also reiterated a Buy rating on the stock with a $82.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ATXI:
